Dr Adeodata R. Kekitiinwa is a Ugandan born certified pediatrician, Associate Clinical Professor of Pediatrics at Baylor College of Medicine, Executive Director for Baylor College of Medicine Children’s Foundation-Uganda (Baylor-Uganda) and serve as the Site Leader for the  Baylor Uganda Clinical Research Site (CRS #31798) which is affiliated with the Johns Hopkins University Kampala HIV Clinical Trial Unit (JHU Kampala CTU).

She leads a team of 457 personnel that offer both comprehensive HIV/AIDS/TB care and research activities at the Baylor Uganda Clinical Center of Excellence (COE).  In addition, she provides technical assistance to Uganda Ministry of Health (MOH) through participating and sharing best practices on various technical working groups.

Through her leadership, Baylor-Uganda has provided comprehensive HIV/AIDS/TB services through strengthening health systems and district led programming in 4 regional blocks of Arua, Soroti, Moroto and Fort portal covering 30 districts from 2010-2016/17. These regions have shown the highest significant reduction in HIV prevalence as per the Uganda Public Health Assessment fact sheets of Sep 2017.  Currently, she leads teams that provide technical assistance to Rwenzori region, Fort portal (08 districts), providing comprehensive family centered pediatric and adolescent HIV/AIDS/TB services through the same approach above.


As a Principal Investigator, she has conducted ARROW and CHAPAS Studies at Baylor-Uganda. ARROW is the largest pediatric ARV trial to date that has contributed to several policy changes internationally, by producing evidence for the inclusion of Abacavir as a first line ART drug for children”. Since 2014, when she joined the JHU Kampala CTU as a CRS Leader for the Baylor-Uganda CRS, the CRS has done an outstanding job conducting studies in Cure, PrEP, and Treatment for pregnant mothers, children and women/youth-at-risk. Since our approval as a CRS, we have been conducting both IND/non-IND phase I-III trials for NIH/DAIDS networks (IMPAACT,HPTN); and have been among the  top enrollers in the IMPAACT, and HPTN Protocols includes the CURE protocol.